American Society of Clinical Oncology
Adcetris Breakthrough: Six-Year Survival Data Reinforce Its Impact in Hodgkin Lymphoma Treatment
SG Tylor
Seagen has made a significant announcement regarding the updated U.S. Prescribing Information (PI) for Adcetris (brentuximab vedotin). The update includes ...
